Brevan Howard Capital Management’s Pacira BioSciences PCRX Stock Holding History

Brevan Howard Capital Management’s Portfolio PCRX Stock Details PCRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-16,662	Closed	-$431K	–	2396
2025 Q4	$431K	Buy	16,662 +4,797	+40%	+$114K	﹤0.01%	1185
2025 Q3	$306K	Sell	11,865 -15,732	-57%	-$386K	﹤0.01%	1555
2025 Q2	$660K	Buy	27,597 +19,495	+241%	+$491K	﹤0.01%	1242
2025 Q1	$201K	Sell	8,102 -25,711	-76%	-$616K	﹤0.01%	985
2024 Q4	$637K	Buy	+33,813	New	+$594K	﹤0.01%	552
2024 Q2	–	Sell	-7,395	Closed	-$216K	–	1329
2024 Q1	$216K	Sell	7,395 -7,634	-51%	-$235K	﹤0.01%	773
2023 Q4	$507K	Buy	+15,029	New	+$440K	0.01%	474

Other funds holding PCRX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

DPCM

Doma Perpetual Capital Management Miami, Florida $431M AUM 13.21% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Brevan Howard Capital Management's PCRX Position: Q1 2026 in Review

Brevan Howard Capital Management sold out of Pacira BioSciences (PCRX) in Q1 2026, closing a stake of 16,662 shares — an estimated $431K sold.

Brevan Howard Capital Management first reported a position in PCRX in Q4 2023 and held it in 7 quarters. The position peaked at $660K in Q2 2025. 242 funds tracked by Wall St. Rank hold PCRX as of Q1 2026.

Brevan Howard Capital Management reported no remaining Pacira BioSciences position as of Q1 2026 after selling out during the quarter.
Brevan Howard Capital Management sold 16,662 Pacira BioSciences shares in Q1 2026, an estimated $431K.
Brevan Howard Capital Management first reported a position in Pacira BioSciences in Q4 2023 and held it in 7 quarters.
Brevan Howard Capital Management's Pacira BioSciences position peaked at $660K in Q2 2025.
242 funds tracked by Wall St. Rank held Pacira BioSciences as of Q1 2026.

Based on Brevan Howard Capital Management's 13F filing for Q1 2026, filed 15 May 2026.